The transition from preclinical development to clinical trials is a critical, with approximately 89% of drugs failing. Nearly half of these failures stem from unexpected and unmanageable human ...

US FDA to Phase ... development of monoclonal antibody therapies and other drugs with "human-relevant methods," including the use of AI-based models. The new approach would help improve drug ...

The new approach would help improve drug safety, lower research and development costs and drug ... which are expected to be rolled out in phases. REUTERS ...